GSK statement on meningitis vaccination in the UK

Issued: London

GSK is delighted to have reached an agreement with the UK’s Department of Health that will enable babies in the UK to receive its meningitis B vaccine through the NHS immunisation schedule.

We have moved rapidly to conclude negotiations since we acquired the vaccine from Novartis at the beginning of March.

We believe the agreement we have reached offers fair value for the NHS and allows a reasonable return for GSK to ensure that we can continue to invest in creating new treatments and vaccines.